NASDAQ:BIB ProShares Ultra Nasdaq Biotechnology (BIB) Price, Holdings, & News $41.57 -3.96 (-8.70%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIB alerts:Sign Up Key Stats Today's Range$40.69▼$43.4850-Day Range$45.53▼$58.3352-Week Range$40.72▼$69.56Volume21,777 shsAverage Volume13,693 shsMarket Capitalization$46.56 millionAssets Under Management$50.47 millionDividend Yield2.26%Net Expense Ratio0.95%Aggregate RatingModerate Buy ETF OverviewProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.Read More… Remove Ads ProShares Ultra Nasdaq Biotechnology ExpensesTypeBIBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.53%0.53%Other Expenses0.40%0.30%0.49%0.43%0.52%Total Expense1.15%0.70%0.72%0.68%0.71%Fee Waiver-0.20%-0.45%-0.50%-0.30%-0.55%Net Expense0.95%0.61%0.63%0.62%0.60% Receive BIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares Ultra Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address BIB ETF News HeadlinesProShares Ultra Nasdaq Biotechnology declares quarterly distribution of $0.3964December 24, 2024 | msn.comProShares Ultra Nasdaq Biotechn (^BIB-IV)September 16, 2024 | ca.finance.yahoo.comTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.April 4, 2025 | Priority Gold (Ad)ProShares Ultra Nasdaq BiotechnologyAugust 20, 2024 | morningstar.comBio-Techne backs Harvard spinout making 'ultra-sensitive' blood testing techJuly 30, 2024 | bizjournals.comProShares Ultra Bloomberg Natural Gas: Trading Short-Term Tailwinds (Rating Upgrade)April 29, 2024 | seekingalpha.comSee More Headlines BIB ETF - Frequently Asked Questions How have BIB shares performed this year? ProShares Ultra Nasdaq Biotechnology's stock was trading at $50.66 on January 1st, 2025. Since then, BIB shares have decreased by 18.3% and is now trading at $41.41. View the best growth stocks for 2025 here. How do I buy shares of ProShares Ultra Nasdaq Biotechnology? Shares of BIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares Ultra Nasdaq Biotechnology investors own include Westmoreland Coal (WLB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Salesforce (CRM). Fund Details IssuerProShares Fund NameProShares Ultra Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIB Inception Date4/6/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings318 Fund Statistics Assets Under Management$53.87 million Average Daily Volume$6,897.20 Discount/Premium0.08% Leveraged2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume4 Put Options3 Call Options1 Short Interest2,400 shs Miscellaneous Outstanding Shares1,120,000Beta1.63 Creation Unit50,000 Creation Fee$250.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Top 10 BIB HoldingsNASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: 41.67%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: 35.72%NASDAQ BIO INDEX SWAP BNP PARIBASHolding Weight: 21.42%NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONALHolding Weight: 9.87%NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: 9.39%Gilead Sciences (NASDAQ:GILD)Holding Weight: 7.57%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: 7.10%Amgen (NASDAQ:AMGN)Holding Weight: 6.98%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 6.78%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.24%Full Holdings Details This page (NASDAQ:BIB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.